Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T12:51:40.100Z.
Calculation as of: 2026-10-06T12:51:40.100Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e2f3ec51e074b036058196f7f903a3cac1545bb57f25a27b7ce4fd0c255fbf9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$251.64M
PS Ratio
59.69
TTM Avg
46.85
3Y Avg
41.58
5Y Avg
41.58
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $245.65M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | 1.11 | 1.71 | 2.09 | 1.59 |
| InflaRx N.V. (IFRX)vs › | $247.45M | N/A | 1866.99 | 1234.73 | 1234.73 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $239.89M | 0.46 | 0.51 | 0.49 | 0.63 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.64M | 59.69 | 46.85 | 41.58 | 41.58 |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | 23.12 | 76.33 | 78.08 | 78.08 |
| Biodesix, Inc. (BDSX)vs › | $236.56M | 2.30 | 1.47 | 2.05 | 2.05 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $264.05M | 2.19 | 1.86 | 1.92 | 2.22 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
